Ocular Tracer for TDP-43

About Amydis Diagnostics

Amydis Diagnostics is developing a first-in-class, non-invasive diagnostic platform that uses proprietary ocular tracers to detect molecular biomarkers in the eye via routine eye exams. This technology targets major unmet needs in neurodegenerative (e.g., Alzheimer's, Parkinson's, ALS), ophthalmic, and cardiovascular diseases by enabling earlier and more accessible diagnosis. The company is advancing its pipeline through human clinical trials with support from significant NIH grants and foundation awards, positioning itself to leverage the existing, widespread infrastructure of eye care providers as a new front line for systemic disease detection.

Therapeutic Areas